LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Translational Autoimmunity, Volume 2
Treatment of Autoimmune Diseases
- 1st Edition - January 5, 2022
- Editor: Nima Rezaei
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 4 3 9 0 - 9
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 5 9 7 5 - 2
Translational Autoimmunity: Treatment of Autoimmune Diseases, Volume Two in the Translational Immunology series, focuses on advances in therapeutic modalities in autoimmune diseas… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteTranslational Autoimmunity: Treatment of Autoimmune Diseases, Volume Two in the Translational Immunology series, focuses on advances in therapeutic modalities in autoimmune diseases. Efficacy and safety of not only the current biologic therapies, but also novel drug targets are discussed. Therapeutic targeting of B regulatory cells, T regulatory cells, as well as the immunomodulation effects of nanoparticles and organisms are also covered, along with our understanding and future challenges of prognostic significance of treatments in autoimmune diseases.
- Covers the clinical aspects and treatment of autoimmunite diseases
- Meets the needs of basic scientists, clinicians and translational scientists and industry partners
- Mentions each and every key concept after background is drawn
- Supported by a systematic appraisal of the most recent evidence
- Helps students at all academic levels, but is also applicable to scientists who work with autoimmunity
Clinical immunologists; Endocrinologists; Microbiologists; Neurologists; Oncologists; Rheumatologists. Clinicians, research scientists, and industry partners
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Preface
- Series editor biography
- Acknowledgment
- Abbreviations
- Chapter 1: Introduction on therapeutic opportunities for autoimmunity
- Abstract
- 1: Introduction
- 2: From the very first known treatment to the recent developments in therapeutic strategies
- 3: Conclusion
- References
- Chapter 2: Innate lymphoid cells as therapeutic targets in autoimmune diseases
- Abstract
- 1: Introduction
- 2: The biology of innate lymphoid cells
- 3: Properties and functions of ILCs
- 4: ILC in autoimmune diseases
- 5: ILCs as immunoregulators in autoimmune diseases
- 6: ILC as a potential therapeutic target in autoimmune diseases
- 7: Future perspectives
- 8: Conclusion
- References
- Chapter 3: B regulatory cells in patients with autoimmune diseases: Pathogenic significance and therapeutic potential
- Abstract
- 1: Introduction
- 2: Identification of Breg cells
- 3: Functional properties
- 4: B regulatory cells and autoimmunity: Pathogenic significance
- 5: Therapeutic potential
- 6: Conclusion
- References
- Chapter 4: Regulatory T cells in autoimmunity and potential therapeutic targets
- Abstract
- 1: Introduction
- 2: Discovery of Treg cells
- 3: Development and activation of Treg cells
- 4: FoxP3—The transcriptional master regulator of Treg cells
- 5: Phenotype of Treg cells
- 6: Treg/T cell subtypes with regulatory function
- 7: Protocols for estimation of Treg cells in the peripheral blood
- 8: Isolation of Treg cells for therapeutic purposes
- 9: Tissue-resident Treg cells
- 10: Clinical and translational significance of Treg cells
- 11: Regulatory T cells (Tregs) as potential therapeutic targets
- 12: Conclusion
- References
- Chapter 5: Application of IL-6 antagonists in autoimmune disorders
- Abstract
- 1: Introduction
- 2: Signaling
- 3: Roles of IL-6
- 4: IL-6 in ADs and autoimmune-related disorders
- 5: Laboratory clues
- 6: IL-6 blockade
- 7: Conclusion
- References
- Chapter 6: The search for monomer-interaction-based alternative TNF-α therapies
- Abstract
- 1: Introduction
- 2: TNF-α in relation to stages in life
- 3: Structure of TNF-α
- 4: TNF-α therapies
- 5: Conclusion
- References
- Chapter 7: Generation of thymic cells from pluripotent stem cells for basic research and cell therapy
- Abstract
- Acknowledgments
- 1: Introduction
- 2: Thymus organogenesis
- 3: Thymus function
- 4: Common thymic disorders
- 5: Human pluripotent stem cells to TECs: A new frontier
- 6: Mimicking development in vitro to generate hPSC-derived anterior foregut endoderm
- 7: Generating thymic epithelial progenitor cells in vitro
- 8: hPSC-derived thymic epithelial cells
- 9: In vitro coculture systems to model thymic function
- 10: Conclusion
- References
- Chapter 8: The NLRP3 inflammasome pathway in autoimmune diseases: a chronotherapeutic perspective?
- Abstract
- Fundings
- 1: Introduction
- 2: The NLRP3 inflammasome
- 3: NLRP3 and autoimmune diseases
- 4: The clock and autoimmune diseases
- 5: NLRP3 as a chronotherapeutic target for autoimmune diseases treatment
- 6: Conclusion
- References
- Chapter 9: Plasmocyte depletion in autoimmune diseases
- Abstract
- 1: Introduction
- 2: The plasmocyte
- 3: New drugs targeting the humoral immunity
- 4: Drugs in the pipeline
- 5: Autoimmune diseases that may benefit from plasmocyte targeting
- 6: Conclusion
- References
- Chapter 10: Biological aging and autoimmunity
- Abstract
- 1: Introduction
- 2: Immunosenescence
- 3: Immune and autoimmune theories of aging
- 4: Autoimmune diseases, cancer, and their relations with aging
- 5: Conclusion
- References
- Chapter 11: Efficacy and safety of immune checkpoint inhibitors and cytokine therapy in autoimmune diseases
- Abstract
- 1: Introduction
- 2: Immunogenicity of mAbs and its effect on efficacy and safety
- 3: Inflammatory cytokine inhibition in autoimmune diseases
- 4: ICIs in autoimmune disease
- 5: Conclusion
- References
- Chapter 12: Nutritional implications for the pathophysiology and treatment of autoimmune disorders
- Abstract
- 1: Introduction
- 2: Body composition and metabolic health
- 3: Dietary patterns
- 4: Macronutrients
- 5: Micronutrients
- 6: Additional non-nutrient dietary factors
- 7: Conclusion
- References
- Chapter 13: Dysbiosis and probiotic applications in autoimmune diseases
- Abstract
- 1: Introduction
- 2: Dysbiosis in autoimmune diseases
- 3: Dysbiosis in autoimmune diabetes
- 4: Dysbiosis in autoimmune thyroid diseases
- 5: Dysbiosis in rheumatoid arthritis
- 6: Dysbiosis in systemic lupus erythematosus
- 7: Dysbiosis in Sjögren’s syndrome
- 8: Probiotic applications in autoimmune diseases
- 9: Probiotics in autoimmune diabetes
- 10: Probiotics in autoimmune thyroid diseases
- 11: Probiotics in rheumatoid arthritis
- 12: Probiotics in systemic lupus erythematous
- 13: Probiotics in Sjögren’s syndrome
- 14: Conclusion
- References
- Chapter 14: Precision medicine to manage chronic immune-related conditions
- Abstract
- Acknowledgments
- 1: Introduction
- 2: Immunosenescence
- 3: Diabetes mellitus
- 4: Atherosclerotic cardiovascular disease
- 5: Musculoskeletal conditions and arthritis
- 6: Mental health conditions
- 7: Cancer
- 8: Conclusion
- References
- Chapter 15: New advanced therapy medicinal products in treatment of autoimmune diseases
- Abstract
- 1: Introduction
- 2: Autoimmune disorders
- 3: Conclusion
- References
- Chapter 16: Targeting autoimmune disorders through metal nanoformulation in overcoming the fences of conventional treatment approaches
- Abstract
- 1: Introduction
- 2: Nanotechnology and nanomaterials
- 3: Targeting of metal nanoparticles for autoimmune conditions
- 4: Safety concern of metallic nanoparticles
- 5: Conclusion
- References
- Chapter 17: Immunomodulatory effects of parasites on autoimmunity
- Abstract
- 1: Introduction
- 2: Mechanism of action in helminth therapy
- 3: Application and protective roles of helminth therapy
- 4: Current challenges in helminth therapy
- 5: Animal models for helminth therapy
- 6: Immunomodulatory roles of parasites on inflammatory or autoimmune diseases
- 7: Leishmaniasis and autoimmune disorders
- 8: Toxoplasmosis and autoimmune disorders
- 9: Conclusion
- References
- Chapter 18: Prediction of autoimmune diseases: From bench to bedside
- Abstract
- 1: Introduction
- 2: Using genetics to estimate the risk of developing AIDs
- 3: Epigenetics to predict AIDs
- 4: Using antibodies and serum biomarkers to predict AIDs
- 5: Perspectives
- 6: Prevention
- 7: Conclusion
- References
- Index
- No. of pages: 486
- Language: English
- Edition: 1
- Published: January 5, 2022
- Imprint: Academic Press
- Paperback ISBN: 9780128243909
- eBook ISBN: 9780323859752
NR
Nima Rezaei
Professor Nima Rezaei gained his medical degree (MD) from Tehran University of Medical Sciences and subsequently obtained an MSc in Molecular and Genetic Medicine and a PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also spent a short-term fellowship of Pediatric Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital. Professor Rezaei is now the Full Professor of Immunology and Vice Dean of Research, School of Medicine, Tehran University of Medical Sciences, and the co-founder and Head of the Research Center for Immunodeficiencies. He is also the founding President of the Universal Scientific Education and Research Network (USERN). Professor Rezaei has already been the Director of more than 55 research projects and has designed and participated in several international collaborative projects. Professor Rezaei is an editorial assistant or board member for more than 30 international journals. He has edited more than 35 international books, has presented more than 500 lectures/posters in congresses/meetings, and has published more than 1,000 scientific papers in the international journals.
Affiliations and expertise
Professor, Department of Immunology, School of Medicine; Head, Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences; Founding President, Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA),Universal Scientific Education and Research Network (USERN),Tehran, IranRead Translational Autoimmunity, Volume 2 on ScienceDirect